BERKELEY HEIGHTS, N.J., April 7, 2008 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that presentations related to Genasense(R) (oblimersen sodium) Injection, the Company's lead anticancer compound will be featured at the annual meeting of the American Association for Cancer Research (AACR). The meeting will be held in San Diego, CA from April 12-16, 2008. The subject matter of several abstracts, which are relevant to both the Company's ongoing randomized Phase 3 trial of Genasense in patients with advanced melanoma, and also to any subsequent regulatory filings that may ensue from that trial, include the following:
Pharmacokinetics (PK) of oblimersen in subjects with mild and moderate renal impairment. Authors: Quereshi A, et al.
Summary: Describes the PK of Genasense in patients with impaired kidney function that may be relevant for prescribers.
Poster session: Sunday, April 13, 2008; 8:00 am.
Population pharmacokinetics (PK) of dacarbazine and Genasense in adult patients with advanced melanoma. Authors: Rezai K, et al.
Summary: Describes the PK of both Genasense and dacarbazine (the chemotherapy drug given to all patients in the Phase 3 melanoma study) and how these drugs interact when co-administered in human subjects.
Poster session: Sunday, April 13, 2008; 8:00 am.
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi- synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.
This press release may contain forward-looking statements with respect
to business conducted by Genta Incorporated. By their nature,
forward-looking statements and forecasts involve risks and uncertainties
because they relate to events and depend on circumstances that will occur
in the future. Forward- looking statements include, without limitation,
-- the Company's ability to obtain necessary regulatory approval for
Genasense(R) from the U.S. Food and Drug Administration ("FDA") or
European Medicines Agency ("EMEA");
-- the safety and efficacy of the Company's products or product
-- the Company's assessment of its clinical trials;
-- the commencement and completion of clinical trials;
-- the Company's ability to develop, manufacture, license and sell its
products or product candidates;
-- the Company's ability to enter into and successfully execute license
and collaborative agreements, if any;
-- the adequacy of the Company's capital resources and cash flow
projections, and the Company's ability to obtain sufficient financing
to maintain the Company's planned operations;
-- the adequacy of the Company's patents and proprietary rights;
-- the impact of litigation that has been brought against the Company and
its officers and directors and any proposed settlement of such
-- the Company's ability to retain compliance with the NASDAQ's listing
-- the other risks described under Certain Risks and Uncertainties Related
to the Company's Business, as contained in the Company's Annual Report
on Form 10-K and Quarterly Report on Form 10-Q.
The Company does not undertake to update any forward-looking
statements. There are a number of factors that could cause actual results
and developments to differ materially. For a discussion of those risks and
uncertainties, please see the Company's Annual Report on Form 10-K for 2007
and its most recent quarterly report on Form 10-Q.
Genta Investor Relations
|SOURCE Genta Incorporated|
Copyright©2008 PR Newswire.
All rights reserved